← FDA DRUG APPROVALS
FDA ANDA · ANDA212181
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE
Sponsor: EMCURE PHARMS LTD
APPLICATION
ANDA212181
TYPE
ANDA
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINENone (Tentative Approval)
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE 600MG · TABLET
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINENone (Tentative Approval)
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE 50MG · TABLET
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINENone (Tentative Approval)
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE 300MG · TABLET
Approval history
2024-12-05UNKNOWN · Original · standardTA
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.